Patents Assigned to Takeda Pharmaceuticals North America, Inc.
  • Patent number: 9278096
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: March 8, 2016
    Assignees: H. Lundbeck A/S, Takeda Pharmaceuticals North America, Inc.
    Inventor: Marianne Dragheim
  • Publication number: 20120065207
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Application
    Filed: October 27, 2011
    Publication date: March 15, 2012
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • Publication number: 20120065215
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Application
    Filed: November 14, 2011
    Publication date: March 15, 2012
    Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • Publication number: 20120065236
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Application
    Filed: September 8, 2011
    Publication date: March 15, 2012
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • Publication number: 20110311620
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 22, 2011
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Publication number: 20110201617
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Application
    Filed: November 12, 2008
    Publication date: August 18, 2011
    Applicants: H. LUNDBECK A/S, TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Nicholas Moore, Marianne Dragheim, Aneil Batra, Jin Chon
  • Publication number: 20110053978
    Abstract: Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provided.
    Type: Application
    Filed: December 11, 2008
    Publication date: March 3, 2011
    Applicants: H. LUNDBECK A/S, TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Silke Miller, Nanco Hefting, Eva Elstrup Jensen, Aneil Batra, Jin Chon
  • Publication number: 20100311756
    Abstract: The present invention relates to methods for reducing the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular dysfunction following a cardiac insult in a subject in need of treatment thereof. Moreover, the present invention also relates to methods of delaying the onset of heart failure symptoms or reducing the incidence of cardiovascular events following a cardiac insult in a subject in need of treatment thereof.
    Type: Application
    Filed: January 19, 2010
    Publication date: December 9, 2010
    Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Lin Zhao, Robert Hamlin, Yingjie Chen
  • Publication number: 20100204252
    Abstract: The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone.
    Type: Application
    Filed: December 22, 2009
    Publication date: August 12, 2010
    Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventor: Stuart R. Kupfer
  • Publication number: 20090074863
    Abstract: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.
    Type: Application
    Filed: November 25, 2008
    Publication date: March 19, 2009
    Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventor: Rajneesh Taneja
  • Publication number: 20090075950
    Abstract: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.
    Type: Application
    Filed: November 25, 2008
    Publication date: March 19, 2009
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventor: Rajneesh Taneja
  • Publication number: 20060293371
    Abstract: The present invention provides a compound having, as a modification group to be eliminated from a prodrug, a group represented by the formula: wherein each symbol is as defined in the specification. According to the present invention, the development of a prodrug based on the modification of a nitrogen-containing heterocycle and the like has become possible.
    Type: Application
    Filed: June 13, 2003
    Publication date: December 28, 2006
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventor: Keiji Kamiyama
  • Publication number: 20050208494
    Abstract: A protein having an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:1, SEQ ID:8, SEQ ID NO:11 or SEQ ID NO:15 is useful as, for example, a diagnostic marker for digestive diseases, immune diseases associating thymic disorders, pancreatic diseases, diabetes, genital diseases, central nerve system diseases, circulatory diseases, muscular diseases, cancer, etc. A compound promoting or inhibiting the activity of this protein which is obtained by a screening method with the use of the protein is usable as, for example, a preventive or a remedy for the above diseases.
    Type: Application
    Filed: May 13, 2003
    Publication date: September 22, 2005
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Atsushi Nakanishi, Hiroyuki Miya, Toshi Iwama